Investigations into the efficacy of multi-component cocaine vaccines.
Bioorg Med Chem Lett
; 28(16): 2779-2783, 2018 09 01.
Article
em En
| MEDLINE
| ID: mdl-29317163
ABSTRACT
Although cocaine addiction remains a serious health and societal problem in the United States, no FDA-approved treatment has been developed. Vaccines offer an exciting strategy for the treatment of cocaine addiction; however, vaccine formulations need to be optimized to improve efficacy. Herein, we examine the effectiveness of a tricomponent cocaine vaccine, defined as having its hapten (GNE) and adjuvant (cytosine-guanine oligodeoxynucleotide 1826, CpG ODN 1826) covalently linked via the immunogenic protein ovalbumin (OVA). The tricomponent vaccine (GNE-OVA-CpG 1826) and a vaccine of analogous, individual components (GNE-OVA+CpG ODN 1826) were found to similarly induce highly specific anticocaine antibody production in mice and block cocaine's stimulant effects in hyperlocomotor testing.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vacinas
/
Ovalbumina
/
Adjuvantes Imunológicos
/
Cocaína
Limite:
Animals
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article